New antiemetic gets FDA nod

Article

Orally available Emend (aprepitant) from Merck has received FDA approval for use with other antiemetics for the prevention of nausea and vomiting associated with initial and repeated courses of moderately and highly emetogenic chemotherapy. The drug was tested in 866 breast cancer patients who had never before undergone emetogenic chemotherapy and was used in combination with ondansetron and dexamethasone. The new drug is available in 80- and 125-mg capsules with a recommended dose of 125-mg one hour prior to chemotherapy on day one, followed by 80-mg daily on days two and three of the treatment cycle.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series
© 2025 MJH Life Sciences

All rights reserved.